Babad, J., A. Geliebter, and T. P. DiLorenzo. 2010. T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes. Immunology 131:459-465
De Jesus, M., S. K. Chow, R. J. Cordero, S. Frases, and A. Casadevall. 2010. Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryot Cell 9:1018-1028
Abboud, N., S. K. Chow, C. Saylor, A. Janda, J. V. Ravetch, M. D. Scharff, and A. Casadevall. 2010. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med 207:2395-2405
Jesus, M. D., A. M. Nicola, S. K. Chow, I. R. Lee, S. Nong, C. A. Specht, S. M. Levitz, and A. Casadevall. 2010. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence 1:500-508
Pericolini, E., E. Gabrielli, G. Bistoni, E. Cenci, S. Perito, S. K. Chow, F. Riuzzi, R. Donato, A. Casadevall, and A. Vecchiarelli. 2010. Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage. PLoS One 5:e12720
Chow, S. K., and A. Casadevall. 2011. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 29:1891-1898
Eisenman, H. C., S. K. Chow, K. K. Tse, E. E. McClelland, and A. Casadevall. 2011. The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence 2:329-336
Vecchiarelli, A., E. Pericolini, E. Gabrielli, S. K. Chow, F. Bistoni, E. Cenci, and A. Casadevall. 2011. Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. Immunotherapy 3:997-1005
Matthew Croken, Kim Lab
Brooks, C. F., M. E. Francia, M. Gissot, M. M. Croken, K. Kim, and B. Striepen. 2011. Toxoplasma gondii sequesters centromeres to a specific nuclear region throughout the cell cycle. Proc Natl Acad Sci U S A 108:3767-3772
Janda, A., and A. Casadevall. 2010. Circular dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. Mol Immunol 47:1421-1425
Abboud, N., S. K. Chow, C. Saylor, A. Janda, J. V. Ravetch, M. D. Scharff, and A. Casadevall. 2010. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med 207:2395-2405
Katakowski, J. A., and D. Palliser. 2010. siRNA-based topical microbicides targeting sexually transmitted infections. Curr Opin Mol Ther 12:192-202
Katakowski, J. A., and D. Palliser. 2011. Optimizing siRNA delivery to the genital mucosa. Discov Med 11:124-132
Garforth, S. J., R. A. Domaoal, C. Lwatula, M. J. Landau, A. J. Meyer, K. S. Anderson, and V. R. Prasad. 2010. K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies. J Mol Biol 401:33-44
Miller EH, Obernosterer G, Raaben M, Herbert AS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Dye JM, Whelan SP, Brummelkamp TR, Chandran K. 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. doi:10.1038/emboj.2012.53
Liu, T. B., Y. Wang, S. Stukes, Q. Chen, A. Casadevall, and C. Xue. 2011. The F-Box protein Fbp1 regulates sexual reproduction and virulence in Cryptococcus neoformans. Eukaryot Cell 10:791-802
Xu, X., C. Vilcheze, Y. Av-Gay, A. Gomez-Velasco, and W. R. Jacobs, Jr. 2011. Precise null deletion mutations of the mycothiol synthesis genes reveal their role in isoniazid and ethionamide resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 55:3133-3139